As previously disclosed, Mirna Therapeutics, Inc. (the “Company”) entered into a Lease Termination Agreement and Release (the “Settlement Agreement”) in May 2017 with G&I VII Encino Trace II LP (the “Landlord”) to terminate that certain lease agreement dated June 24, 2016 by and between the Company and the Landlord (the “Lease Agreement”). to the Settlement Agreement, the termination of the Lease Agreement was to be effective as of, and contingent upon, the Landlord’s execution of a new lease with a third party. On June 23, 2017, the termination of the Lease Agreement became effective upon entry by the Landlord into an agreement with a third party regarding the premises previously covered under the Lease Agreement with the Company.

About Mirna Therapeutics, Inc. (NASDAQ:MIRN)

Mirna Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of micro ribonucleic acid (RNA)-based oncology therapeutics. The Company is developing mimics of naturally occurring microRNAs that are designed to restore the tumor suppressor activity and aid appropriate anti-tumor immune response. This approach is known as microRNA replacement therapy. Its lead product candidate, MRX34, a mimic of naturally occurring microRNA-34 (miR-34) encapsulated in a liposomal nanoparticle formulation, has demonstrated clinical proof of concept as a single agent in its ongoing Phase I clinical trial. The Company’s RNA molecules function as natural microRNAs when they enter human cells. These RNA molecules, which it calls microRNA mimics, may be used to replace those tumor suppressor microRNAs that are lost, or under expressed, in cancer cells. Its other preclinical product candidates include miR-215, miR-101, miR-16 and let-7.